Martin & Co. Inc. TN Invests $5.26 Million in Omnicell, Inc. $OMCL

Martin & Co. Inc. TN acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 126,712 shares of the company’s stock, valued at approximately $5,261,000. Omnicell makes up 0.8% of Martin & Co. Inc. TN’s portfolio, making the stock its 23rd biggest holding.

A number of other institutional investors also recently modified their holdings of OMCL. BlackRock Inc. bought a new position in Omnicell during the second quarter worth $313,044,000. Dimensional Fund Advisors LP increased its stake in Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC boosted its position in shares of Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after purchasing an additional 62,733 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Omnicell by 2.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after buying an additional 27,497 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Up 0.2%

Shares of Omnicell stock opened at $35.58 on Friday. The firm has a market cap of $1.62 billion, a PE ratio of 42.36, a P/E/G ratio of 0.89 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell, Inc. has a 1 year low of $29.06 and a 1 year high of $55.00. The stock has a fifty day moving average price of $40.38 and a 200-day moving average price of $39.68.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on OMCL shares. Wells Fargo & Company dropped their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Craig Hallum reaffirmed a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday. KeyCorp reduced their price target on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.